E
Sell
5/2/2024Upgraded
MIRA Pharmaceuticals, Inc. (MIRA) was upgraded to E+ from E on 5/2/2024 due to a large increase in the growth index, volatility index and valuation index. Operating cash flow increased 41.24% from -$1.76M to -$1.04M, earnings per share increased from -$0.2631 to -$0.1735, and EBIT increased 3.28% from -$3.16M to -$3.06M.
E
Sell
2/1/2024Upgraded
MIRA Pharmaceuticals, Inc. (MIRA) was upgraded to E from E- on 2/1/2024 due to a substantial increase in the solvency index and valuation index. The quick ratio increased from 0.01 to 6.76, and debt to equity declined from 1.57 to 0.01.
E
Sell
10/26/2023None
MIRA Pharmaceuticals, Inc. (MIRA) was downgraded to E- from U on 10/26/2023.
